Avelumab binds PD-L1 on target cells and, via its intact IgG1 Fc, engages Fc gamma receptors (e.g., CD16) on NK cells to trigger antibody-dependent cellular cytotoxicity (ADCC), killing PD-L1–expressing cells; it also blocks PD-1/PD-L1 to restore T-cell activity (indirect).